SAREPTA THERAPEUTICS INC's ticker is SRPT and the CUSIP is 803607100. A total of 362 filers reported holding SAREPTA THERAPEUTICS INC in Q1 2021. The put-call ratio across all filers is 1.27 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,822 | +13.6% | 30,945 | +3.2% | 0.01% | +12.5% |
| Q2 2023 | $3,365 | -36.6% | 30,000 | -23.7% | 0.01% | -38.5% |
| Q1 2023 | $5,306 | +10.5% | 39,310 | +3.6% | 0.01% | 0.0% |
| Q4 2022 | $4,803 | -99.9% | 37,960 | 0.0% | 0.01% | +8.3% |
| Q3 2022 | $4,128,000 | +42.7% | 37,960 | 0.0% | 0.01% | +50.0% |
| Q2 2022 | $2,893,000 | -3.0% | 37,960 | 0.0% | 0.01% | +14.3% |
| Q1 2022 | $2,983,000 | -15.0% | 37,960 | -1.8% | 0.01% | -22.2% |
| Q4 2021 | $3,511,000 | +5.4% | 38,660 | +2.7% | 0.01% | 0.0% |
| Q3 2021 | $3,330,000 | -26.8% | 37,660 | -35.2% | 0.01% | -30.8% |
| Q2 2021 | $4,548,000 | +56.2% | 58,160 | +45.4% | 0.01% | +30.0% |
| Q1 2021 | $2,912,000 | -54.6% | 39,990 | +6.7% | 0.01% | -58.3% |
| Q4 2020 | $6,420,000 | +16.6% | 37,462 | -3.5% | 0.02% | 0.0% |
| Q3 2020 | $5,505,000 | +667.8% | 38,811 | +776.1% | 0.02% | +380.0% |
| Q2 2020 | $717,000 | +62.6% | 4,430 | -2.7% | 0.01% | +66.7% |
| Q1 2020 | $441,000 | -44.5% | 4,554 | -26.0% | 0.00% | -40.0% |
| Q4 2019 | $795,000 | -75.6% | 6,153 | -85.8% | 0.01% | -75.0% |
| Q3 2019 | $3,257,000 | -66.6% | 43,242 | -42.5% | 0.02% | -59.2% |
| Q2 2019 | $9,755,000 | +132.3% | 75,180 | +150.3% | 0.05% | +96.0% |
| Q1 2019 | $4,200,000 | +49.0% | 30,031 | +14.6% | 0.02% | +31.6% |
| Q4 2018 | $2,818,000 | -32.9% | 26,205 | -12.7% | 0.02% | -24.0% |
| Q3 2018 | $4,200,000 | +17.2% | 30,031 | +12.1% | 0.02% | +8.7% |
| Q2 2018 | $3,585,000 | +70.0% | 26,800 | -8.8% | 0.02% | +64.3% |
| Q1 2018 | $2,109,000 | +127.8% | 29,400 | +18.9% | 0.01% | +100.0% |
| Q4 2017 | $926,000 | 0.0% | 24,733 | 0.0% | 0.01% | 0.0% |
| Q3 2017 | $926,000 | +12.2% | 24,733 | 0.0% | 0.01% | 0.0% |
| Q2 2017 | $825,000 | +14.9% | 24,733 | 0.0% | 0.01% | 0.0% |
| Q1 2017 | $718,000 | -5.3% | 24,733 | -7.5% | 0.01% | -12.5% |
| Q4 2016 | $758,000 | -49.7% | 26,733 | +8.1% | 0.01% | -52.9% |
| Q3 2016 | $1,508,000 | +226.4% | 24,733 | 0.0% | 0.02% | +240.0% |
| Q2 2016 | $462,000 | +23.2% | 24,733 | +26.9% | 0.01% | +25.0% |
| Q1 2016 | $375,000 | -54.0% | 19,483 | -7.6% | 0.00% | -55.6% |
| Q4 2015 | $815,000 | +21.5% | 21,083 | +1.0% | 0.01% | +12.5% |
| Q3 2015 | $671,000 | +9.8% | 20,883 | +4.0% | 0.01% | +14.3% |
| Q2 2015 | $611,000 | +137.7% | 20,083 | +3.6% | 0.01% | +133.3% |
| Q1 2015 | $257,000 | -19.4% | 19,383 | -11.8% | 0.00% | -25.0% |
| Q4 2014 | $319,000 | -37.0% | 21,983 | -8.3% | 0.00% | -42.9% |
| Q3 2014 | $506,000 | -27.4% | 23,983 | +2.6% | 0.01% | -30.0% |
| Q2 2014 | $697,000 | +29.1% | 23,383 | +4.0% | 0.01% | +11.1% |
| Q1 2014 | $540,000 | +21.6% | 22,483 | +5.1% | 0.01% | +28.6% |
| Q4 2013 | $444,000 | -47.1% | 21,383 | +20.2% | 0.01% | -53.3% |
| Q3 2013 | $840,000 | +27.5% | 17,783 | +2.9% | 0.02% | +15.4% |
| Q2 2013 | $659,000 | – | 17,283 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ikarian Capital, LLC | 399,400 | $35,962,000 | 5.36% |
| Avoro Capital Advisors LLC | 3,125,000 | $281,406,000 | 4.79% |
| Varenne Capital Partners | 324,661 | $29,236,000 | 4.34% |
| Evolutionary Tree Capital Management, LLC | 96,695 | $8,707,000 | 4.18% |
| Ally Bridge Group (NY) LLC | 120,000 | $10,806,000 | 3.78% |
| Casdin Capital, LLC | 1,350,000 | $121,568,000 | 3.43% |
| Ghost Tree Capital, LLC | 100,000 | $9,005,000 | 3.23% |
| GREAT POINT PARTNERS LLC | 145,405 | $13,094,000 | 2.91% |
| Camber Capital Management LP | 825,000 | $74,291,000 | 2.55% |
| Alpha DNA Investment Management LLC | 17,522 | $1,577,000 | 1.00% |